• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Ischemic stroke in patients with POEMS syndrome: a case report and comprehensive analysis of literature.
Conclusion: Comprehensive analysis of literature revealed several trends in patients with ischemic stroke and POEMS syndrome including a low survival rate and a preponderance of cerebral vasculopathy and multiple cerebral arteries affected. Ischemic stroke may be a poor outcome predictor in patients with POEMS syndrome. Further researches focusing on a larger cohort may help in better characterizing and treating this rare complication of POEMS syndrome. PMID: 29179528 [PubMed]
Source: Oncotarget - November 29, 2017 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Distance to Thrombus in acute middle cerebral artery stroke predicts basal ganglia infarction after mechanical thrombectomy.
CONCLUSION: In MCA stroke, the exact site of the occlusion as measured by DT independently predicts the involvement of LSAs and subsequent striatocapsular infarction with high sensitivity and specificity. PMID: 27845905 [PubMed - as supplied by publisher]
Source: Oncotarget - November 16, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Therapeutic effects of umbilical cord blood plasma in a rat model of acute ischemic stroke.
This study provides valuable insights into the development of a safe, effective, and cell-free strategy for the treatment of ischemic brain damage and a much-needed alternative for patients who are ineligible for thrombolytic therapy. PMID: 27816964 [PubMed - as supplied by publisher]
Source: Oncotarget - November 8, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Sub-acute systemic erythropoietin administration reduces ischemic brain injury in an age-dependent manner.
Authors: Thériault P, Le Béhot A, ElAli A, Rivest S Abstract Stroke is associated with neuroinflammation, neuronal loss and blood-brain barrier (BBB) breakdown. Thus far, recombinant tissue-type plasminogen activator (rtPA), the only approved treatment for acute ischemic stroke, increases the risk of intracerebral hemorrhage and is poorly efficient in disaggregating platelet-rich thrombi. Therefore, the development of safer and more efficient therapies is highly awaited. Encouraging neuroprotective effects were reported in mouse models of ischemic stroke following administration of erythropoietin (EPO). However, ...
Source: Oncotarget - June 2, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research